Zimulti Acomplia Report - News about the diet drug rimonabant

ZimultiAcompliaReport

Since 2004, your INDEPENDENT source of news about diet drug Acomplia / Zimulti

Neither affiliated with nor endorsed by Sanofi-Aventis

What Is Zimulti / Acomplia / Rimonabant?

Clinical Trials

Side-Effects

What Doctors Say?

When & Where Can I Get It?

Other Diet Drugs

Zimulti / Acomplia & Smoking

	The Zimulti Acomplia Report - News of Rimonabant
	Now that a promising new prescription anti-obesity drug, rimonabant, is actually available in the U.K., Germany and 40 other countries, the launch of the most anticipated weight-loss medication since Fen-phen is generating a great deal of excitement among millions of obese and seriously overweight Americans and Europeans. The drug, marketed in Europe as Acomplia, may ultimately be sold in the United States as Zimulti -- but that day appears several years off after an FDA advisory panel voted against sale of rimonabant in summer 2007 out of concern over its depressive side effects. The Zimulti Acomplia Report, updated daily, will track the continuing efforts of Sanofi to get rimonabant approved for sale in the U.S. The Zimulti Acomplia Report also will provide news and reviews related to rimonabant so those eager to try this new anti-obesity drug will have the latest information on availability, weight-loss results and side-effects.
	Zimulti Acomplia News for August 2008-- News About Rimonabant
	Study: Acomplia (Rimonabant) May Increase Risk of Colorectal Cancer Targeting Peripheral CB1 Receptors May Avoid Acomplia Side-Effects
	Zimulti Acomplia News for July 2008-- News About Rimonabant
	Global Sales of Diet Drug Acomplia Edge Up to $50 Million in 2nd Quarter
	Zimulti Acomplia News for June 2008-- News About Rimonabant
	Acomplia Significantly Improves Glucose Control of Diabetic Patients
	Zimulti Acomplia News for May 2008-- News About Rimonabant
	Cat Scans Confirm Acomplia Reduces Dangerous Abdominal Obesity
	Zimulti Acomplia News for April 2008-- News About Rimonabant
	Diet Drug Acomplia (Rimonabant) Still Seen as a Winner by Sanofi Acomplia Found to Up Risk of Anxiety and Depression in Heart Study
	Zimulti Acomplia News for March 2008-- News About Rimonabant
	Taranabant Produces Weight-Loss at One-Tenth the Acomplia Dosage NICE Recommends Acomplia Be Available Through Britain's Health Service Acomplia May Cause Depression by Blocking TRPV1 Receptor in Brain Report: Taranabant Side-Effects May Be Similar to Acomplia (Rimonabant) Diet Drug Acomplia May Help Block Development of Alcoholic Fatty Liver Acomplia Again Turned Down for Insurance Coverage in Germany Pfizer Lagging Behind Merck in Developing Diet Drug Acomplia Competitor
	Zimulti Acomplia News for February 2008-- News About Rimonabant
	Sales of Acomplia Lag, But Sanofi Still Has High Hopes for Rimonabant
	Zimulti Acomplia News for January 2008-- News About Rimonabant
	Will Diet Drug Taranabant Be This Year's Rimonabant (Acomplia / Zimulti)?
	Zimulti Acomplia News for December 2007-- News About Rimonabant
	Taranabant Moves Ahead But Merck Admits Psychiatric Effects Seen in Trial UK Panel Inclined 'Not to Recommend' Diet Drug Acomplia (Rimonabant)
	Zimulti Acomplia News for November 2007-- News About Rimonabant
	Study Links Diet Drug Acomplia to 'Severe Adverse Psychiatric Events' Study: Acomplia Weight Loss 'Modest' and Safe-Effects Are Concern Class Action Lawsuit Filed Against Sanofi Over Acomplia / Zimulti Sanofi Allowed to Inform Patients Taking Acomplia It Aids Glucose Control Acomplia Sales Disappoint; No Major Improvement Seen Until 2009
	Zimulti Acomplia News for October 2007-- News About Rimonabant
	Taranabant Yields Encouraging Results With 'Generally Mild' Side-Effects Merck to Report on Taranabant, Acomplia Competitor, on Oct. 24th
	Zimulti Acomplia News for September 2007-- News About Rimonabant
	Study Finds Diet Drug Acomplia Significantly Reduces Visceral Fat Sanofi: No Plans to Try to Sell Acomplia in U.S. for Three or Four Years Vernalis Says Diet Drug Similar to Acomplia (Rimonabant) Shows Promise Taranabant, Merck's Competitor to Diet Drug Acomplia, Nears End of Study
	Zimulti Acomplia News for August 2007-- News About Rimonabant
	Copies of Diet Drug Acomplia (Rimonabant) Being Widely Sold in India Sanofi Offers Little Hope for Early U.S. Sale of Diet Drug Acomplia / Zimulti
	Zimulti Acomplia News for July 2007-- News About Rimonabant
	Top Marketeer Returns to Merck to Promote Diet Drug Acomplia Competitor Diet Drug Acomplia Sales Dwarfed by Initial Sales of Diet Pill alli Sanofi Still Hopeful Diet Drug Acomplia Will Make It to U.S. Market Acomplia (Rimonabant) Doubles Risk of Depression -- European Regulators UK Regulator: One in 10 on Acomplia Experiences Psychiatric Side Effects Diet Drug Acomplia to Remain on Market in Europe With Stronger Warning Europeans to Further Decide on Diet Drug Acomplia This Week New Study Finds Acomplia (Rimonabant) May Help Prevent Liver Damage Sanofi: Diet Drug Acomplia Requires Indefinite Use to Keep Weight Off
	Zimulti Acomplia News for June 2007-- News About Rimonabant
	Sanofi Withdraws Bid to Sell Diet Drug Acomplia (Rimonabant) in U.S. New European Recommendations on Acomplia May Be Published June 29 Diet Pill Acomplia (Rimonabant) Gets Reprieve in Europe Diet Drug Acomplia Users in Germany Get Bad News on Reimbursement If You Want Acomplia (Rimonabant), You Won't Find It Anywhere as Zimulti Diet Drug Acomplia Safety Data to Be Reviewed by Europeans Next Week Acomplia/Zimulti Dealt Blow as FDA Panel Says Keep It Off the U.S. Market Sanofi: No 'Causal Relationship' Proven Between Acomplia and 'Suicidality' Key FDA Meeting on Rimonabant Opens With Focus on 'Suicidality' Zimulti Acomplia Report Covering FDA Meeting on Diet Pill Rimonabant FDA: 30 Percent of U.S. Patients on Diet Drugs Also on Antidepressants FDA Delay on Diet Drug Acomplia (Rimonabant) Tied to Suicide, Seizures Rimonabant (Acomplia / Zimulti) Facing Moment of Truth in Week Ahead Diet Drug Rimonabant (Acomplia / Zimulti) on Sale in United Arab Emirates Diet Pill Acomplia Now Widely Available in Mexican Border Pharmacies
	Zimulti Acomplia News for May 2007-- News About Rimonabant
	Added Health Claims for Diet Drug Acomplia Questioned by British Experts Do Indian Versions of Diet Drug Rimonabant Work the Same as Acomplia? FDA Action on Zimulti (Rimonabant) May Be Slowed by Avandia Scare Sanofi 'Examining Options' Against Sellers Offering Generic Rimonabant 2nd Generic Version of Rimonabant (Acomplia / Zimulti) Hits Market in India Generic Version of Rimonabant (Acomplia / Zimulti) Launched in India Raids in Europe Crack Ring Selling Counterfeit Acomplia on the Internet The Acomplia Report Newsletter Is Renamed the Zimulti Acomplia Report Sanofi Explains Why Diet Drug Acomplia Will Be Zimulti in the U.S. Diet Drug Acomplia (Rimonabant) European Sales Seen as Disappointing
	Zimulti Acomplia News for April 2007-- News About Rimonabant
	Diet Drug Acomplia (Rimonabant) Approved for Sale in Brazil It's Official. Diet Drug Acomplia (Rimonabant) to Use Name Zimulti in U.S. Diet Drug Acomplia (Rimonabant) Approved for Sale in Switzerland Competitor for Diet Drug Rimonabant Now Has a Name: Taranabant
	Zimulti Acomplia News for March 2007-- News About Rimonabant
	Diet Drug Acomplia Concerns to Be Aired by FDA Advisory Panel in June Few in France to Get Reimbursement for Diet Drug Acomplia Diet Pill Acomplia Seen Becoming 'Gold Standard' for Treating Obesity Diet Drug Acomplia Now on Sale in Some Mexican Border Pharmacies
	Zimulti Acomplia News for February 2007-- News About Rimonabant
	Diet Drug Acomplia Seen Unlikely to Get FDA OK for 'Metabolic Syndrome' Latest Acomplia Delay May Be Tied to Bid to Get U.S. Approval for Diabetes Diet Pill Acomplia (Rimonabant) Hits New Three-Month Delay at U.S. FDA FDA Approves Diet Pill Alli (Low-Dose Xenical) for Nonprescription Sale Diet Drug Acomplia Gets French OK Limited to Obese Diabetics Most Significant "Wait Loss" for Diet Drug Acomplia Is Loss of Sanofi Lead
	Zimulti Acomplia News for January 2007-- News About Rimonabant
	UK Company Plans Trial of Diet Drug With Same Target as Acomplia Sanofi to Improve 'Communication,' But Not About FDA and Acomplia Diet Pill Rimonabant (Acomplia / Zimulti) Not Yet Available in Mexico Diet Drug Acomplia Rejected for Coverage by German Health Insurance Expert Says Overactive Endocannibanoid System May Be Key to Obesity FDA Approves New Diet Drug, But Not Acomplia or Alli (Also Not for Humans) Long-Term Data Needed on Diet Drugs to Prove Benefits Outweigh Risks Diet Pills Acomplia (Rimonabant) and Alli (Low-Dose Xenical) Stalled at FDA
	Zimulti Acomplia News for Jan. to Dec. 2006 -- Click for 2006 Archive
	Zimulti Acomplia News for Jan. to Dec. 2005 -- Click for 2005 Archive
	Zimulti Acomplia News for Jan. to Dec. 2004 -- Click for 2004 Archive

Free! Join

Zimulti / Acomplia

Forum

Discussions

Consumer Ad Alert!

Privacy Policy | Terms and Disclaimers | About the Zimulti Acomplia Report

Contact Us

We subscribe to the HONcode principles of the HON Foundation.

This is an independent news site reporting on rimonabant, a diet drug developed by Sanofi-Aventis Inc., which is marketing it in Europe under the trademarked name Acomplia and in the United States under the trademarked name Zimulti. Nothing on this site is intended to infringe on those trademarks. Nothing on this site is intended as medical advice. The information provided here is for informational purposes only. Always consult a doctor or medical professional with questions you may have regarding a medical condition.

Last Updated: 08/02/2008